{
  "retracted": false,
  "timestamp": 1311638400000,
  "updates": [
    {
      "timestamp": 1587076965501,
      "identifier": {
        "doi": "10.1007/s10637-011-9713-6"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s10637-011-9687-4"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy"
}
